Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | CXCR3 | P49682 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373338 | 0.90 | CXCR3 (0.72) | RAB9ACXCR3KMT2AKDM4EMEN1 | |
| SCHEMBL14373337 | 0.90 | CXCR3 (0.73) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14470428 | 0.90 | CXCR3 (0.58) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14373332 | 0.85 | RAB9A (0.63) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14373284 | 0.82 | CXCR3 (0.80) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14373339 | 0.81 | CXCR3 (0.57) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14373358 | 0.81 | RAB9A (0.67) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14373323 | 0.81 | CXCR3 (0.84) | RAB9ANPC1CXCR3KMT2AMEN1 | |
| SCHEMBL14470561 | 0.81 | RAB9A (0.67) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 | |
| SCHEMBL14373348 | 0.80 | CXCR3 (0.67) | RAB9ANPC1CXCR3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | RAB9A 1111/4885NPC1 234/4885CXCR3 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.